Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain.
Esteban DaudénGlauber Pacelli Gomes de LimaSusana ArmestoEnrique Herrera-AcostaDavid VidalEva VillarasaRaquel RiveraPablo de la CuevaAntonio MartorellFerran BallescaIsabel BelinchónGregorio CarreteroLourdes RodríguezAntonio Sahuquillo-TorralbaJosep Pujol-MontcusíLaura SalgadoAntonio Sahuquillo-TorralbaPablo Coto-SeguraOfelia BaniandrésRosa FeltesMercé AlsinaMar Llamas-VelascoPublished in: Dermatology and therapy (2021)
In our study, we found that cumulative secukinumab drug survival for psoriasis patients for the period 6-18 months was in the range of real-world evidence studies. Additionally, we observed a relatively high long-term survival rate at 24 months (74.3%).
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- primary care
- peritoneal dialysis
- emergency department
- ankylosing spondylitis
- rheumatoid arthritis
- cross sectional
- patient reported outcomes
- systemic lupus erythematosus
- patient reported
- disease activity
- hidradenitis suppurativa